Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

Beth Overmoyer, MD
Published: Friday, Dec 19, 2014


Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Overmoyer says in a study of about 30 patients with inflamatory breast cancer, it was determined that average time to tumor failure was 19 months, and 3-year overall survival was approximately 49%. Disease-free survival was also short.

The outlook for this patient population is particularly challenging, says Overmoyer. Currently, chemotherapy is the only option for these patients. Future research should focus on targeted therapies for inflammatory triple-negative breast cancer.

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Overmoyer says in a study of about 30 patients with inflamatory breast cancer, it was determined that average time to tumor failure was 19 months, and 3-year overall survival was approximately 49%. Disease-free survival was also short.

The outlook for this patient population is particularly challenging, says Overmoyer. Currently, chemotherapy is the only option for these patients. Future research should focus on targeted therapies for inflammatory triple-negative breast cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x